Systems in Nuclear Medicine 423
These TACs can be further normalized by plotting, from point-to-point, the
ratio of the values of one ROI TAC to the values of another ROI TAC that is
taken as a reference.
For quantification some reference is needed, and this can be the tracer con-
centration in arterial plasma (blood sampling required) or some other tissue
(a different area of the same image).
In PET studies, the tracers are introduced into the body by intravenous
injection or inhalation. The tracers are mixed with blood in the heart chambers
to give a nearly constant concentration in arterial blood (model input). The
concentration of the tracer delivered to the tissue capillaries can be obtained
from any peripheral artery, and the amount of tracer delivered to the tissue
is proportional to the blood flow (perfusion).
Some of the possibilities for finding the input function to an organ are by
external measurement in the left ventricle, aorta, or large artery as a function
of time (i.e., the respective TAC). This method, which requires fast response
equipment to cope with the temporal sampling requirements of the particular
input function, is also limited to those cases in which the left ventricle or a
great vessel is located within the limits of the image [33,34].
Statistical methods that will be discussed later can also be used to effectively
obtain these input functions.
Depending on their biochemical properties, the radiotracers used in PET
studies are grouped in two broad categories.
The first category comprises the nonspecific radiotracers that trace a bio-
chemical path and lead to the measurement of the extraction parameters
of a tissue which describe its uptake and metabolism. Examples of these
radiotracers are
15
OH
2
, which is an inert, freely diffusible tracer used to mea-
sure cerebral blood flow;
18
FDG, which traces the initial phases of glucose
metabolism but does not follow Kreb’s cycle after phosphorylation and is,
therefore, effectively retained in cells, permitting the evaluation of glucose
metabolism in tissue; and
18
F-fluoromisonidazole, which is a bioreductor
drug that follows an intracellular path of reduction and can be used to localize
viablehypoxic tissue.The kineticsof theradiopharmaceuticals ofthis kindcan
be evaluated through simple systems consisting of one or two compartments
apart from plasma.
The second category includes specific radiotracers involved in interactions
with a receptor, a carrier, or a specific interaction site. Examples of these radio-
tracers are
11
C-flumazenil, which is an antagonist with high affinity and selec-
tivity for central benzodiazepine receptors, and
11
C-SCH23390, an antagonist
withhigh affinityand selectivityfor dopamine D1receptors. Both radiotracers
are used to study alterations in the density and affinity of central recep-
tors. The behavior of the radiopharmaceuticals in this category is generally
assessed by means of three-compartment models: free, nonmetabolized lig-
and in plasma; free ligand in tissues; and ligand specifically bound to tissues.
In tracer studies, the data acquisition methodology and the recommended
data analysis method depend on the aim and type of study being performed.